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Thirty-three patients with T3,N2,MO or T4,N2,MO, nonsmall-cell lung cancer (NSCLC) took part in a phase 2 study in an attempt to evaluate the feasability of neoadjuvant chemotherapy followed by surgery and thoracic radiotherapy. Chemotherapy consisted of daily administration of the following treatment: etoposide, 100 mg/m2; cisplatin, 25 mg/m2; ifosfamide, 1.5 g/m2; and mesna, 1.8 g/m2 for 4 days. Three cycles were planned starting every 21 days. Responding patients underwent a thoracotomy in order to attempt a resection and then received a 45 Gy of thoracic radiotherapy. The results of response and resection rates have been published and the present final report deals with the longterm results. Chemotherapy induced a 55 percent partial response rate and a 15 percent complete response rate allowing a complete resection in 55 percent of the patients. Complete remission was histologically confirmed for the five complete responders. Although the median survival was short (10 months), six patients were long-term survivors (3-year survival rate: 19 percent). Survival was significantly influenced by the type of resection: patients for whom a complete resection was possible survived the longest with a median survival three times that of the other patients. Modalities of reNon-small-cell lung cancer (NSCLC) is frequently associated with a metastatic disease at some time during the microscopic stage rather than when it becomes clinically detectable.' Patients with a locally advanced NSCLC, particularly stage N2, are sometimes considered for surgery, but resection is frequently followed by metastatic relapses.2 There are two underlying problems where local and regional extension in NSCLC is concerned: first, this extension limits the possibility for a surgeon to carry out a lapses differed according to the results of surgery: 8 of the 15 patients who did not undergo a complete surgical resection experienced a local relapse during the first 18 months of follow-up whereas in the complete resection group, central nervous system metastasis was the main site of relapse. We conclude that the neoadjuvants ifosfamide, cisplatin, and etoposide in patients with locally advanced NSCLC are feasible to use and allow a 19 percent 3-year survival rate. These results are the rationale of an ongoing randomized study comparing neoadjuvant chemotherapy followed by surgery and surgery alone. This study is designed to test whether neoadjuvant chemotherapy improves survival of patients with locally advanced NSCLC.
( For all patients, staging procedure included clinical examination, chest radiographs, computed tomographic (CT) scan of chest, upper abdomen, and brain, fiberoptic bronchoscopy, and bone scanning. Staging was carried out according to the fourth edition of the UICC TNM classification.5'6 Patients with gross mediastinal involvement, ie, more than two ipsilateral nodal stations with mediastinal lymph nodes greater than 20 mm on CT scan, and widened carina or main bronchus distortion suggestive of subcarenal lymph nodes, were considered as having locally advanced NSCLC and were included directly in the study; patients for whom this staging procedure failed to demonstrate bulky mediastinal involvement had cervical mediastinoscopy.
Chemotherapy consisted of daily administration of the following treatment: etoposide, 100 mg/mi2; cisplatin, 25 mg/mi2; ifosfamide, 1.5 g/m2; and mesna, 1.8 g/m2 for 4 days. A cycle started every 21 days. Patients were evaluated for response at the start of each cycle of chemotherapy by clinical examination and chest radiograph. Based on the response after the second cycle of chemotherapy, patients with evidence of major response underwent a new complete staging procedure to evaluate it precisely and a resection was planned at that time, whereas other patients underwent a third cycle before complete staging procedure. Chemotherapy-induced tumor response was defined according to WHO:7 a complete response was defined as the complete disappearance of all lesions; a partial response was defined as equal to or greater than a 50 percent reduction in the product of the two longest perpendicular diameters of the indicator lesions measured on CT scan. For patients who achieved a complete or a partial response, a thoracotomy was scheduled 2 weeks after hematologic recovery with an attempt at curative resection and mediastinal lymph node disection. A complete resection was defined as resection of all macroscopic disease and normal histologic features of the margin. Patients with stable or progressive disease were not planned for surgery. All patients received thoracic radiotherapy (45 Gy, postoperatively or as unique local treatment).
A x2 test was used for comparison of frequency distribution of qualitative variables. Survival was defined as the time from the first day of treatment to the date of death. Time to progression was defined as the time from the first course of treatment to the time of relapse for responding patients or progression for patients with stable disease. Probability of survival was estimated by the Kaplan-Meier method. The main toxic reaction of ifosfamide, cisplatin, and etoposide chemotherapy was a moderate to severe hematologic one. Ninety-two percent of the patients experienced a grade 3 to 4 neutropenia toxic reaction during the chemotherapy program and 60 percent experienced a grade 3 to 4 thrombopenia (according to the WHO scale). Among them, 10 patients developed a grade 2 to 3 infection. These patients required a hospitalization lasting for 6 days and intravenous antibiotics. Blood transfusions were given to six patients and platelet transfusions were given to four others. One patient died of central nervous system hemorrhage.
Surgery and Microscopic Findings
The results of surgery and pathologic examination of the specimen are shown in Table 1 with a 19 percent 3-year survival. The modality of relapse differs when patients who underwent a complete resection are compared with others, the central nervous system remaining the first site of failure in the former group.
Neoadjuvant chemotherapy was tested in patients with NSCLC in an attempt to increase the resectability of the tumor and to treat the microscopic metastatic disease known to be responsible for the majority of failures in surgically treated patients. Several published trials have been reviewed extensively."9"0 Most of them are feasibility studies in stage III NSCLC. Obviously, the heterogeneity of eligibility criteria from one study to another prevents general conclusions on the usefulness of neoadjuvant chemotherapy. In addition, the majority of the studies, including the one reported herein, have been designed as phase 2 trials and, therefore, they cannot answer the following questions. Is the operability of patients with NSCLC increased by neoadjuvant chemotherapy? Is overall survival improved by this approach? However, it is possible to conclude that neoadjuvant chemotherapy has an antitumor activity: most studies report a 60 percent objective response rate, including a significant number of complete responses and a 50 percent complete resection rate. Neoadjuvant chemotherapy does not increase morbidity after surgery except when it is combined with preoperative radiation therapy.1"10
The results of our study show similar rates of chemotherapy-induced tumor responses, complete pathologic responses, and complete resections. The staging procedure we used could be discussed. In the literature, some studies used a radiographic definition of mediastinal lymph node enlargement (clinical N2)"112 whereas others used a strict pathologic definition of this involvement.'3"14 Although a real comparison of these two groups of studies is not possible for methodologic reasons, there is no major difference when resection rates and survivals are considered. In our study, we decided to avoid mediastinoscopy for patients with bulky N2 on CT scan and to determine N2 disease pathologically in the other cases. We observed no difference in resection rate and survival when these two groups were compared. In addition, three of six of the long-term survival patients had a biopsy-proven N2 stage tumor at time of inclusion.
The analysis of survival in our study showed that long-term survival can be achieved in patients with N2 disease receiving neoadjuvant chemotherapy. Median survival was calculated as 10 months by the Kaplan-Meier method and suggested a weak advantage of neoadjuvant ifosfamide, cisplatin, and etoposide. However, the median survival is only a rough indicator of prognosis, particularly in a small size population and the 3-year survival rate might be a better variable to evaluate a study. The 19 percent 3-year survival observed in our study can be regarded as sufficiently favorable to consider our protocol as feasible. A clear survival advantage has been observed for patients who underwent complete resection. However, it is not possible to assume that surgical excision is the only reason for such a result and some other factors, including response to chemotherapy, might be considered.
In the published studies, median survival varied from 8 to 24 months. This wide range might be explained by (1) true differences in efficacy between protocols, and (2) heterogeneity of eligibility criteria. When available, long-term survival reports show that a 15 percent 3-year survival rate can be expected for patients who benefit from neoadjuvant chemotherapy. These results are not a proof of the chemotherapy efficacy but deserve further randomized studies Ifosfamide, Cisplatin, and Etoposide in Non-Small-Cell Lung Cancer (Pujol et al) designed to test the effectiveness of neadjuvant chemotherapy in NSCLC. In this setting, a possible study design to determine the survival advantage of neoadjuvant chemotherapy might be to randomize patients with stage N2 NSCLC between neoadjuvant chemotherapy followed by surgery and surgery alone. A recent study investigating this comparison concluded that neoadjuvant chemotherapy increases the median survival of stage Illa NSCLC. 15 In March 1990, we started a randomized phase 3 trial based on a similar design. The aim of this study is to determine whether enhanced response and resection rates could increase survival of patients with NSCLC treated by ifosfamide, cisplatin, and etoposide neoadjuvant chemotherapy. Other trials based on alternative methods of randomization are also ongoing and one could expect that these studies could define the place for neoadjuvant chemotherapy in NSCLC.
